MS-based phosphoproteomic of cytarabine-treated FLT3-ITD cells

ABSTRACT: ITD mutations in the FLT3 gene occur in the 30% of acute myeloid leukemia patients. The integration of ITD in the tyrosine kinase domain (TKD-ITD) of the FLT3 receptor has been shown to confer resistance to standard chemotherapy treatment. We applied state-of-the-art, high-sensitive, mass spectrometry (MS)-based (phospho)proteomics to investigate the molecular mechanisms underlying the sensitivity to cytarabine therapy in FLT3-ITD cells.

INSTRUMENT(S):

ORGANISM(S): Mus Musculus (mouse)

SUBMITTER: Francesca Sacco  

LAB HEAD: Francesca Sacco

PROVIDER: PXD038638 | Pride | 2023-07-20

REPOSITORIES: Pride